| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 06/24/2009 | CN101466402A Glycosylation engineered antibody therapy |
| 06/24/2009 | CN101461942A Dendritic cell vaccine carrying recombinant human HSP70 polypeptide complexes, preparation method and application |
| 06/24/2009 | CN101461941A Vaccine and preparation method thereof |
| 06/24/2009 | CN101461940A Photobacterium damsela vaccine as well as preparation method and use thereof |
| 06/24/2009 | CN100503639C Recombinant tumor specific antibody and use thereof |
| 06/24/2009 | CN100503638C Protein tau |
| 06/24/2009 | CN100502945C Application of fusion protein of VEGF receptor for treating disease of eye |
| 06/23/2009 | US7550429 treating mammal to a weight reduction or reduction in obesity; biodrug as antilipolytic agents |
| 06/23/2009 | US7550296 Identifying functional insertion sites within the genome of a replication competent target virus; result in an increase in the selectivity and efficiency of gene therapy |
| 06/23/2009 | US7550280 Lipases and uses thereof |
| 06/23/2009 | US7550275 Expression, purification and uses of a Plasmodium falciparum liver stage antigen 1 polypeptide |
| 06/23/2009 | US7550150 Methods of treating or preventing a disease, disorder or condition associated with a viral infection |
| 06/23/2009 | US7550149 Attenuation of cytomegalovirus virulence |
| 06/23/2009 | US7550148 Contacting the target cell with a recombinant HSV particle comprising an altered gD forming a fusion with a peptide ligand to a receptor specific to the cell wherein the altered gD exhibits reduced binding to at least one of the cellular receptors of wild type gD; cell imaging; gene therapy; kits |
| 06/23/2009 | US7550147 Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA) |
| 06/23/2009 | US7550146 Mucin motif found on epithelial tumor cell surfaces; antibody induction; cancer treatment |
| 06/23/2009 | US7550145 Adjuvant compositions |
| 06/23/2009 | US7550144 Antibody capable of reacting with cellular prion protein (PrP) ; for prevention of prion replication; for treatment or prevention of neuropathology such as Creutzfeldt-Jacob Disease |
| 06/23/2009 | US7550143 Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| 06/23/2009 | US7550142 Anti-integrin antibodies, compositions, methods and uses |
| 06/23/2009 | US7550141 Methods for imaging tumor vasculature using conjugates that bind to aminophospholipids |
| 06/23/2009 | US7550140 Stimulation of human T-cells and used to enhance antigen-specific immune responses; immunotherapy |
| 06/23/2009 | CA2389219C Dry powder compositions having improved dispersivity |
| 06/23/2009 | CA2337494C Herpes virus vectors for dendritic cells |
| 06/23/2009 | CA2250078C Processes for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process |
| 06/23/2009 | CA2173822C Cytoplasmic expression of antibodies, antibody fragments and antibody fragment fusion molecules in e. coli |
| 06/23/2009 | CA2139100C New sequences of hepatitis c virus genotypes and their use as therapeutic and diagnostic agents |
| 06/18/2009 | WO2009076542A2 Vaccine directed against adenovirus serotype 14 |
| 06/18/2009 | WO2009076455A2 Methods of treating hematologic cancers using pnp inhibitors such as forodesine in combination with alkylating agents or anti-cd20 agents |
| 06/18/2009 | WO2009076170A2 Combinations of therapeutic agents for treating cancer |
| 06/18/2009 | WO2009076158A1 Compositions for inducing immune responses |
| 06/18/2009 | WO2009076099A1 Dendritic cell targeting compositions and uses thereof |
| 06/18/2009 | WO2009075806A1 Methods and compositions for treating liquid tumors |
| 06/18/2009 | WO2009075646A1 Improved immunizing composition |
| 06/18/2009 | WO2009075344A1 Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof |
| 06/18/2009 | WO2009074867A2 Analysis of mixtures including proteins |
| 06/18/2009 | WO2009074861A2 Improved vaccine |
| 06/18/2009 | WO2009074539A1 Prevention and treatment of otitis media using iga enriched milk |
| 06/18/2009 | WO2009074341A1 Method for producing dendritic cells |
| 06/18/2009 | WO2009074339A1 Remedies for pemphigus containing anti fas ligand antobodies |
| 06/18/2009 | WO2009073916A1 Improved treatment and prophylaxis |
| 06/18/2009 | WO2009073911A1 Treatment and prophylaxis |
| 06/18/2009 | WO2009073905A2 Method for increasing immunoreactivity |
| 06/18/2009 | WO2009058833A3 Mycoplasma bovis vaccine |
| 06/18/2009 | WO2009058355A3 Chloroplast-derived human vaccine antigens against malaria |
| 06/18/2009 | WO2009049013A9 Cholera vaccines |
| 06/18/2009 | WO2009046974A3 Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
| 06/18/2009 | WO2009045464A8 Methods of treating neurological autoimmune disorders with cyclophosphamide |
| 06/18/2009 | WO2009035971A3 Compositions and methods for preventing influenza infection in canines, felines and equines |
| 06/18/2009 | WO2009025806A3 Use of vegfr-2 inhibitors for treating metastatic cancer |
| 06/18/2009 | WO2009024822A3 Diagnostic method and kit |
| 06/18/2009 | WO2009024239A3 Permissive cells and uses thereof |
| 06/18/2009 | WO2009024208A9 Hypoallergenic molecules |
| 06/18/2009 | WO2009003082A3 Immunological compositions as cancer biomarkers and/or therapeutics |
| 06/18/2009 | WO2007109749A8 Methods for preventing and treating amyloidogenic diseases |
| 06/18/2009 | WO2007021841A3 Identification and engineering of antibodies with variant fc regions and methods of using same |
| 06/18/2009 | WO2004039945A3 Preventive and therapeutic aids vaccines |
| 06/18/2009 | WO2004024077A3 Novel composition and methods for the treatment of psoriasis |
| 06/18/2009 | WO2003066830A3 Human monoclonal antibodies against membrane proteins |
| 06/18/2009 | WO2002079494A3 Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof |
| 06/18/2009 | WO2001085908A3 Clasp-1 transmembrane protein |
| 06/18/2009 | US20090156982 Transdermal treatment device and method |
| 06/18/2009 | US20090156790 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| 06/18/2009 | US20090156787 Antibody production elicited by a dna vaccine delivered by electroporation |
| 06/18/2009 | US20090156490 Peptides for diagnostic and therapeutic methods for celiac sprue |
| 06/18/2009 | US20090155887 Vaccine Composition |
| 06/18/2009 | US20090155886 Nucleic acids and polypeptides specific for pathogenic strains of the neisseria genus |
| 06/18/2009 | US20090155845 Molecules designated LDCAM |
| 06/18/2009 | US20090155374 Bioactive agent, a low molecular weight chitosan, and a negatively charged third component; the chitosan dominates on the nanoparticle surface; enhanced permeability for paracellular drug delivery; chewable composition |
| 06/18/2009 | US20090155364 Transdiscal administration of anti-TNFalpha antibodies and growth differentiation factors |
| 06/18/2009 | US20090155351 Solid Vaccine Formulation |
| 06/18/2009 | US20090155350 Chlamydia antigens and protein vaccine |
| 06/18/2009 | US20090155348 Detoxified Recombinant Botulinum Neurotoxin |
| 06/18/2009 | US20090155330 Vaccine Delivery via Microneedle Arrays |
| 06/18/2009 | US20090155314 Dermal filler |
| 06/18/2009 | US20090155313 Vaccine Against Salmonid Rickettsial Septicaemia Based on Arthrobacter Cells |
| 06/18/2009 | US20090155312 Viral variants detection and application |
| 06/18/2009 | US20090155311 Indoleamine 2,3-dioxygenase pathways in the generation of regulatory t cells |
| 06/18/2009 | US20090155310 Hn epitope recognized by avian immune system and antigenic variant newcastle disease viruses carrying changes in the epitope |
| 06/18/2009 | US20090155309 Novel vaccine |
| 06/18/2009 | US20090155308 Powerful vaccine composition comprising lipopeptide and poly I:C as an adjuvant |
| 06/18/2009 | US20090155307 Immunostimulatory nucleic acid oil-in-water formulations and related methods of use |
| 06/18/2009 | US20090155306 Pamps, pathogen associated molecular patterns |
| 06/18/2009 | US20090155305 Manufacture of Vaccines That Contain Both Hepatitis B Virus Surface Antigen and Surfactant |
| 06/18/2009 | US20090155304 Modified Cyanovirin-N Polypeptide |
| 06/18/2009 | US20090155303 Cpg single strand deoxynucleotides for use as adjuvant |
| 06/18/2009 | US20090155302 Antigen Arrays for Treatment of Allergic Eosinophilic Diseases |
| 06/18/2009 | US20090155301 Pseudoinfectious flavivirus and uses thereof |
| 06/18/2009 | US20090155299 Antibodies for the Detection of Bacillus Anthracis and Vaccine Against B. Anthracis Infections |
| 06/18/2009 | US20090155298 Matrix Metalloproteinase 11 Vaccine |
| 06/18/2009 | US20090155297 Methods and Compositions for Inducing an Immune Response Against Multiple Antigens |
| 06/18/2009 | US20090155296 based on a native version of the enzyme from E. corrodens and induces production of antibodies that inhibit the activity of the lysine decarboxylase enzyme in the oral cavity; comprising a substitution at a position corresponding to position 365 of SEQ ID NO:2 |
| 06/18/2009 | US20090155295 Vaccine |
| 06/18/2009 | US20090155294 Hcv vaccines |
| 06/18/2009 | US20090155293 Modified defensins and their use |
| 06/18/2009 | US20090155292 Compositions and methods for the prevention and treatment of autoimmune conditions |
| 06/18/2009 | US20090155291 Method of increasing immunological effect |
| 06/18/2009 | US20090155290 Antigen |
| 06/18/2009 | US20090155289 Furin-cleavable peptide linkers for drug-ligand conjugates |
| 06/18/2009 | US20090155288 Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies |